Sequoia Financial Advisors LLC grew its stake in shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) by 34.5% in the fourth ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

February saw several changes on boards at biotechs, bringing a diverse wealth of experience to support these companies. Read ...